A phase II, randomized, double-blind, placebo-controlled bronchoscopy study to evaluate the effects of lebrikizumab on airway eosinophilic inflammation in patients with uncontrolled asthma on inhaled corticosteroids and a second controller medication
Purpose: The purpose of this study is to see if a medication called Lebrikizumab helps control asthma symptoms by decreasing the amount of inflammation in the lungs. Lebrikizumab is an antibody that attaches to a protein called IL-13. It is believed that IL-13 plays an important role in causing asthma. It is also believed that Lebrikizumab will prevent IL-13 from interacting with other protein and therefore reduce asthma attacks and improve lung function in asthmatics. This study is being done to see if asthma symptoms truly do improve with the use of this medication.
Eligibility: Individuals who are 18-75 years of age, who have been diagnosed with asthma, and who still suffer from asthma symptoms (such as shortness of breath, wheezing, chest tightness) despite the use of daily asthma medications may be eligible to participate in this study.
Sponsor: F. Hoffmann-La Roche Ltd
Principal Investigator: Monica Kraft, MD